A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

Go Back to All Clinical Trials

A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

Brief description of study

This is a multicenter, Phase 1b/2 trial. The Phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

Clinical Study Identifier: s22-01101

ClinicalTrials.gov Identifier: NCT05563220

Principal Investigator: Nancy Chan.

Other Investigators: Yelena Novik, Maryann J Kwa, Douglas K Marks, Nina D'Abreo, Marleen I Meyers, Amanda Marie Talmadge, Sylvia Adams, Danielle Seidman, Caitlin Elizabeth Ryan, Anastasiya Apanasyuk, Ruth Oratz, Natalie Jill Klar, Annmarie Johnson-Rowe, Alexander A Hindenburg.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies